Literature DB >> 6214995

In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim.

H C Neu, P Labthavikul.   

Abstract

Norfloxacin is a quinolinecarboxylic acid compound. We examined the in vitro activity of this compound against gram-positive and -negative species, including anaerobic species. It inhibited 90% (MIC90) of strains of Escherichia coli at 0.05 microgram/ml, Klebsiella sp. at 0.4 microgram/ml, Salmonella and Shigella spp. at 0.1 microgram/ml, Citrobacter sp. at 0.4 microgram/ml, Enterobacter cloacae at 0.2 microgram/ml, Enterobacter aerogenes at 0.4 microgram/ml, and Enterobacter agglomerans at 0.2 microgram/ml. The MICs of Proteus mirabilis, Morganella sp., Proteus vulgaris, Proteus rettgeri, and Providencia sp. were 0.1, 0.2, 0.8, 0.3, and 1.6 micrograms/ml, respectively. The MIC90 of Serratia sp. was 1.6 micrograms/ml, and that of Acinetobacter sp. was 6.3 micrograms/ml. For Pseudomonas aeruginosa the MIC50, the MIC75, and the MIC90 were 0.8, 1.6, and 3.1 micrograms/ml, respectively. The MIC50 of Pseudomonas maltophilia was 3.1 micrograms/ml, and the MIC90 was 12.5 micrograms/ml. Yersinia, Arizona, and Aeromonas all were inhibited at concentrations below 1 microgram/ml, as was Campylobacter. The activity of the compound against gram-positive species was less impressive: the MIC90s of Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus faecalis were 1.6, 6.3, 3.1, and 12.5 micrograms/ml, respectively. All Listeria strains were inhibited by 3.1 micrograms/ml. The activity of norfloxacine was not affected by the type of medium, pH, or inoculum size. There was no major difference between MIC and minimum bactericidal concentration values. Norfloxacin inhibited bacteria in every species which was resistant to ampicillin, carbenicillin, cephalexin, gentamicin, and trimethoprim at concentrations lower than those of aminothiazolyl cephalosporins, moxalactam, and aminoglycosides.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6214995      PMCID: PMC183667          DOI: 10.1128/AAC.22.1.23

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  Comparative in vitro activity of Mk-0366 and other selected oral antimicrobial agents against Neisseria gonorrhoeae.

Authors:  M Y Khan; Y Siddiqui; R P Gruninger
Journal:  Antimicrob Agents Chemother       Date:  1981-08       Impact factor: 5.191

2.  Synergy of azlocillin and mezlocillin combined with aminoglycoside antibiotics and cephalosporins.

Authors:  H C Neu; K P Fu
Journal:  Antimicrob Agents Chemother       Date:  1978-05       Impact factor: 5.191

3.  In vitro antibacterial activity of AM-715, a new nalidixic acid analog.

Authors:  A Ito; K Hirai; M Inoue; H Koga; S Suzue; T Irikura; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

  3 in total
  37 in total

1.  In vitro evaluation of A-56619 (difloxacin) and A-56620: new aryl-fluoroquinolones.

Authors:  J M Stamm; C W Hanson; D T Chu; R Bailer; C Vojtko; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

2.  The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro.

Authors:  J S Wolfson; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

3.  In vitro activity of Ro 23-6240, a new fluorinated 4-quinolone.

Authors:  N X Chin; D C Brittain; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

4.  Susceptibility of multiply antibiotic-resistant pneumococci to the new quinoline antibiotics, nalidixic acid, coumermycin, and novobiocin.

Authors:  M E Gombert; T M Aulicino
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

5.  In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone.

Authors:  E Wakabayashi; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

6.  Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

8.  High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia.

Authors:  W Kern; E Kurrle; E Vanek
Journal:  Klin Wochenschr       Date:  1987-08-17

9.  In vitro activity of ciprofloxacin, a new carboxyquinoline antimicrobial agent.

Authors:  G M Eliopoulos; A Gardella; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

Review 10.  Norfloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  B Holmes; R N Brogden; D M Richards
Journal:  Drugs       Date:  1985-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.